SuperworthBillionToOne BLLN
- Market cap
- $5.1B
- PE
- 166×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 12.8×
- EV/EBIT
- 107×
- Revenue, 12 months
- $397.4M
- +90% on a year ago
- Net margin
- 9.5%
- Free cash flow yield
- 0.7%
BillionToOne trades at 166× trailing earnings. Revenue was $397.4M over the last twelve months, up 90% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| $38.4M | $45.1M | $59M | $66.6M | $83.5M+117% | $96.1M+113% | $108.4M+84% | $109.4M+64% | |
| Cost of revenue | $18.2M | $19.4M | $21M | $23.1M | $25.1M+38% | $27.4M+42% | $29.3M+40% | $32.3M+40% |
| Gross profit | $20.2M | $25.7M | $38M | $43.5M | $58.4M+189% | $68.6M+167% | $79.1M+108% | $77.1M+77% |
| R&D | $9.6M | $11M | $10.4M | $11.8M | $13M+36% | $14.3M+30% | $14.7M+41% | $17.3M+47% |
| SG&A | $23.3M | $26.4M | $29.9M | $33.3M | $35.8M+54% | $44M+67% | $46.6M+56% | $54.3M+63% |
| −$12.6M | −$11.7M | −$2.3M | −$1.6M | $9.6M | $10.3M | $17.8M | $5.5M | |
| Interest expense | $422K | $47K | $40K | $32K | $20K−95% | $3K−94% | $10K−75% | $8K−75% |
| Pre-tax income | −$14.9M | −$11.5M | −$3.9M | −$232K | $5.6M | $6.3M | $18.5M | $7.5M |
| $0 | $24K | $100K | $14.5K | −$129K | $320K+1233% | $539K+439% | −$536K | |
| Net income | −$14.9M | −$11.5M | −$4M | −$246K | $5.7M | $6M | $18M | $8.1M |
| −$1.47 | −$1.13 | −$0.39 | −$0.02 | $0.10 | $0.06 | $0.34 | $0.15 | |
| 10.1M | 10.2M | 10.3M | 10.4M | 15.6M+54% | 39.4M+287% | 53M+414% | 54.5M+424% |
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest BillionToOne's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| CDNACareDx | $3.6B | 33.4× | 19.1× | n/m | 7.8× | +34% | 24.2% |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| Peer median | $13.8B | 35.9× | 32.6× | 25.6× | 6.4× | +8% | 14.1% |
Investors who own it
Investors we follow who held BillionToOne at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.1% of portfolioadded
- Baillie GiffordBaillie Gifford0.1% of portfoliotrimmed
- Polen CapitalPolen Capital0.0% of portfolionew
More on BillionToOne
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .